Literature DB >> 9725901

Binding of insulin-like growth factor (IGF)-binding protein-5 to smooth-muscle cell extracellular matrix is a major determinant of the cellular response to IGF-I.

A Parker1, C Rees, J Clarke, W H Busby, D R Clemmons.   

Abstract

Insulin-like growth factor-binding protein-5 (IGFBP-5) has been shown to bind to fibroblast extracellular matrix (ECM). Extracellular matrix binding of IGFBP-5 leads to a decrease in its affinity for insulin-like growth factor-I (IGF-I), which allows IGF-I to better equilibrate with IGF receptors. When the amount of IGFBP-5 that is bound to ECM is increased by exogenous addition, IGF-I's effect on fibroblast growth is enhanced. In this study we identified the specific basic residues in IGFBP-5 that mediate its binding to porcine smooth-muscle cell (pSMC) ECM. An IGFBP-5 mutant containing alterations of basic residues at positions 211, 214, 217, and 218 had the greatest reduction in ECM binding, although three other mutants, R214A, R207A/K211N, and K202A/R206N/R207A, also had major decreases. In contrast, three other mutants, R201A/K202N/R206N/R208A, and K217N/R218A and K211N, had only minimal reductions in ECM binding. This suggested that residues R207 and R214 were the most important for binding, whereas alterations in K211 and R218, which align near them, had minimal effects. To determine the effect of a reduction in ECM binding on the cellular replication response to IGF-I, pSMCs were transfected with the mutant cDNAs that encoded the forms of IGFBPs with the greatest changes in ECM binding. The ECM content of IGFBP-5 from cultures expressing the K211N, R214A, R217A/R218A, and K202A/R206N/R207A mutants was reduced by 79.6 and 71.7%, respectively, compared with cells expressing the wild-type protein. In contrast, abundance of the R201A/K202N/R206N/R208A mutant was reduced by only 14%. Cells expressing the two mutants with reduced ECM binding had decreased DNA synthesis responses to IGF-I, but the cells expressing the R201A/K202N/R206N/R208A mutant responded well to IGF-I. The findings suggest that specific basic amino acids at positions 207 and 214 mediate the binding of IGFBP-5 to pSMC/ECM. Smooth-muscle cells that constitutively express the mutants that bind weakly to ECM are less responsive to IGF-I, suggesting that ECM binding of IGFBP-5 is an important variable that determines cellular responsiveness.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9725901      PMCID: PMC25505          DOI: 10.1091/mbc.9.9.2383

Source DB:  PubMed          Journal:  Mol Biol Cell        ISSN: 1059-1524            Impact factor:   4.138


  31 in total

1.  Insulin-like growth factor binding proteins in maternal serum throughout gestation and in the puerperium: effects of a pregnancy-associated serum protease activity.

Authors:  L C Giudice; E M Farrell; H Pham; G Lamson; R G Rosenfeld
Journal:  J Clin Endocrinol Metab       Date:  1990-10       Impact factor: 5.958

2.  Insulin-like growth factor binding protein-5 binds to plasminogen activator inhibitor-I.

Authors:  T J Nam; W Busby; D R Clemmons
Journal:  Endocrinology       Date:  1997-07       Impact factor: 4.736

3.  Analysis of serum insulin-like growth factor binding proteins using western blotting: use of the method for titration of the binding proteins and competitive binding studies.

Authors:  P Hossenlopp; D Seurin; B Segovia-Quinson; S Hardouin; M Binoux
Journal:  Anal Biochem       Date:  1986-04       Impact factor: 3.365

4.  The ontogeny and regulation of a 31,000 molecular weight insulin-like growth factor-binding protein in fetal porcine plasma and sera.

Authors:  R H McCusker; D R Campion; D R Clemmons
Journal:  Endocrinology       Date:  1988-05       Impact factor: 4.736

5.  Molecular modeling of protein-glycosaminoglycan interactions.

Authors:  A D Cardin; H J Weintraub
Journal:  Arteriosclerosis       Date:  1989 Jan-Feb

6.  Heparan sulphate bound growth factors: a mechanism for stromal cell mediated haemopoiesis.

Authors:  R Roberts; J Gallagher; E Spooncer; T D Allen; F Bloomfield; T M Dexter
Journal:  Nature       Date:  1988-03-24       Impact factor: 49.962

7.  Binding of insulin-like growth factor (IGF) I or II to IGF-binding protein-2 enables it to bind to heparin and extracellular matrix.

Authors:  T Arai; W Busby; D R Clemmons
Journal:  Endocrinology       Date:  1996-11       Impact factor: 4.736

8.  Evidence for a functional role of endogenously produced somatomedinlike peptides in the regulation of DNA synthesis in cultured human fibroblasts and porcine smooth muscle cells.

Authors:  D R Clemmons; J J Van Wyk
Journal:  J Clin Invest       Date:  1985-06       Impact factor: 14.808

9.  Compartmentalization of a haematopoietic growth factor (GM-CSF) by glycosaminoglycans in the bone marrow microenvironment.

Authors:  M Y Gordon; G P Riley; S M Watt; M F Greaves
Journal:  Nature       Date:  1987 Mar 26-Apr 1       Impact factor: 49.962

10.  The smooth muscle cell. II. Growth of smooth muscle in culture and formation of elastic fibers.

Authors:  R Ross
Journal:  J Cell Biol       Date:  1971-07       Impact factor: 10.539

View more
  14 in total

1.  Insulin-like growth factor-binding protein-2 is required for osteoclast differentiation.

Authors:  Victoria E DeMambro; Laura Maile; Christine Wai; Masanobu Kawai; Teresa Cascella; Clifford J Rosen; David Clemmons
Journal:  J Bone Miner Res       Date:  2012-02       Impact factor: 6.741

Review 2.  The role of insulin-like growth factor binding proteins in development.

Authors:  J M Pell; D A M Salih; L J Cobb; G Tripathi; A Drozd
Journal:  Rev Endocr Metab Disord       Date:  2005-08       Impact factor: 6.514

Review 3.  Implications of the PAPP-A-IGFBP-IGF-1 pathway in the pathogenesis and treatment of polycystic kidney disease.

Authors:  Sonu Kashyap; Julianna D Zeidler; Claudia C S Chini; Eduardo Nunes Chini
Journal:  Cell Signal       Date:  2020-06-20       Impact factor: 4.315

Review 4.  Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases?

Authors:  Terry J Smith
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

Review 5.  IGF-I/IGFBP system: metabolism outline and physical exercise.

Authors:  R Gatti; E F De Palo; G Antonelli; P Spinella
Journal:  J Endocrinol Invest       Date:  2012-06-18       Impact factor: 4.256

6.  Differences in gene expression between strabismic and normal human extraocular muscles.

Authors:  Amy L Altick; Cheng-Yuan Feng; Karen Schlauch; L Alan Johnson; Christopher S von Bartheld
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-08-03       Impact factor: 4.799

7.  Duplicated zebrafish insulin-like growth factor binding protein-5 genes with split functional domains: evidence for evolutionarily conserved IGF binding, nuclear localization, and transactivation activity.

Authors:  Wei Dai; Hiroyasu Kamei; Yang Zhao; Jun Ding; Zhou Du; Cunming Duan
Journal:  FASEB J       Date:  2010-01-15       Impact factor: 5.191

8.  Insulin-like growth factor-binding protein-5 inhibits osteoblast differentiation and skeletal growth by blocking insulin-like growth factor actions.

Authors:  Aditi Mukherjee; Peter Rotwein
Journal:  Mol Endocrinol       Date:  2008-02-21

Review 9.  Regulation of muscle mass by growth hormone and IGF-I.

Authors:  C P Velloso
Journal:  Br J Pharmacol       Date:  2008-06       Impact factor: 8.739

Review 10.  Insulin-like growth factor-binding protein-5 (IGFBP-5): a critical member of the IGF axis.

Authors:  James Beattie; Gordon J Allan; Jennifer D Lochrie; David J Flint
Journal:  Biochem J       Date:  2006-04-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.